Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris.
- Author:
Ai-Ping YU
1
;
Bing-Xing SHI
;
Chun-Na DONG
;
Zhong-Hua JIANG
;
Zu-Ze WU
Author Information
1. Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cloning, Molecular;
Electroporation;
Hirudins;
biosynthesis;
genetics;
Humans;
Pichia;
genetics;
metabolism;
Recombinant Fusion Proteins;
biosynthesis;
genetics;
Reverse Transcriptase Polymerase Chain Reaction;
Tissue Plasminogen Activator;
biosynthesis;
genetics
- From:
Chinese Journal of Biotechnology
2005;21(4):553-557
- CountryChina
- Language:Chinese
-
Abstract:
To combine the fibrinolytic with anticoagulant activities for therapy of thrombotic deseases, a fusion protein made of tissue-type plasminogen activator (t-PA) and hirudin was constructed and expressed in chia pastoris. To improve thrombolytic properties of t-PA and reduce bleeding side effect of hirudin, FXa-recognition sequence was introduced between t-PA and hirudin molecules.The anticoagulant activity of hirudin can be target-released through cleavage of FXa at thrombus site. t-PA gene and hirudin gene with FXa-recognition sequence at its 5'-terminal were obtained by RT-PCR and PCR respectively. The fusion protein gene was cloned into plasmid pIC9K and electroporated into the genome of Pichia pastoris GS115. The expression of fusion protein was induced by methanol in shaking flask and secreted into the culture medium. Two forms of the fusion protein, single-chain and double-chain linked by a disulfide bond (due to the cleveage of t-PA at Arg275-Ile276), were obtained. The intact fusion protein retained the fibrinolytic activity but lacked any anticoagulant activity. After cleavage by FXa, the fusion protein liberated intact free hirudin to exert its anticoagulant activity. So, the fusion protein is a bifunctional molecule having good prospect to develop into a new targeted therapeutic agent with reduced bleeding side effect for thrombotic diseases.
